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Abstract 
Tumor invasion and metastasis remain a major cause of mortality in breast cancer patients. It 
was reported that BP1, a homeobox isoform of DLX4, is overexpressed in 80% of breast 
cancer patients and in 100% of estrogen receptor negative (ER-) tumors. The prevalence of 
BP1 positive cells and the intensity of BP1 immunoreactivity increased with the extent of 
ductal proliferation and tumorigenesis. These findings imply that BP1 may play an important 
role in ER- breast cancer. We sought to determine the effects and mechanisms of BP1 on cell 
proliferation and metastasis using ER- Hs578T cells as a model. Cells were transfected with 
either pcDNA3.2 plasmid containing BP1 gene, or pcDNA3.2 vector, then selected and 
cloned. Overexpression of BP1 increased cell proliferation rate by 2-5 fold (p<0.005), and 
enhanced the in vitro invasive activity by 25-65 fold (p<0.001). Microarray experiments were 
performed to identify differentially expressed genes when BP1 is overexpressed. The gene 
expression profile of the transfected cell lines were compared, resulting in 71 differentially 
expressed genes with a fold-change of >=2.0. Of those genes, 49 were up-regulated and 22 
were down-regulated. Significant pathways were identified involving cell proliferation and 
metastasis. These data demonstrated that overexpression of BP1 significantly enhanced cell 
proliferation and metastatic potential in ER- Hs578T cells. Further analysis with more ER- cell 
lines and patient samples is warranted to establish BP1 as a therapeutic target for ER- breast 
cancer.  
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INTRODUCTION 
Breast cancer is one of the most common malig-
nancies affecting women and was expected to be di-
agnosed in approximately 192,370 new cases of inva-
sive tumor, as well as an estimated 62,280 additional 
cases of in situ tumor in the United States in 2009, and 
about 40,170 women were expected to die from the 
disease [1]. Homeobox genes that were originally 
identified in Drosophila, encode a family of transcrip-
tional  factors essential for axial and appendicular 
patterning and  organogenesis [2]. Further studies Journal of Cancer 2010, 1 
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demonstrated that homeobox genes are an important 
class of master regulatory genes responsible for or-
chestrating developmental processes in many species. 
These genes are characterized by a common 
180-nucleotide sequence coding for a 60-amino-acid 
domain known as homeodomain, which contains a 
helix-turn-helix DNA binding motif. This motif di-
rects specific binding of downstream target genes that 
may be activated or repressed. In vitro assays show 
that all HOX proteins can bind to similar DNA motifs 
with a core sequence of TAAT [3] [4]. Homeobox 
genes are divided into families on the basis of the 
level of similarity among their respective homeodo-
mains [5]. It is estimated that the human genome in-
cludes at least 200 homeobox genes [6]. Homeobox 
genes are classified into two groups. A large family of 
homeobox genes, also referred to as HOX genes, are 
structurally and functionally homologous to the 
homeotic complex (HOM-C) of Drosophila [2]. In 
mice (Hox genes) and humans (HOX genes), there are 
at least 39 of them, organized in four clusters, loca-
lized on different chromosomes (HOXA at 7p15.3, 
HOXB at 17q21.3, HOXC at 12q13.3, and HOXD at 
2q31), [7] each containing 9 to 11 genes arranged in a 
homologous sequence. A small family, such as MSX 
and Engrailed (EN) groups only has two or three 
members. Most homeobox gene families, such as the 
NKX, PAX and Distal-less (DLX) groups, are inter-
mediate in size and contain five to nine members. In 
humans, there have been at least seven members dis-
covered in the DLX group, to which BP1/DLX4 be-
longs. DLX4 has at least two distinct spliced variants 
[8]. Recently, many homeobox genes were found to be 
aberrantly expressed in a variety of cancers, including 
those of the breast, kidney, skin and leukemia, sug-
gesting that they may also contribute to the progres-
sion of tumors [9] [10] [11] [12]. Studies of loss of 
function or deregulation of homeobox genes in breast 
cancer strongly implicate a role for these genes in 
cellular transformation, alterations in cell cycle and 
apoptosis, and progression to a metastatic phenotype. 
Homeobox genes are expressed in carcinoma cell 
lines, as well as the corresponding embryonic tissues 
from which these tumor cells are derived [13] [14]. 
The deregulated expression of homeobox genes has 
been described in many solid tumors and derivative 
cell lines.  
BP1, a splice variant of DLX4, is mapped to 
chromosome 17q21[8] and is involved in the regula-
tion of diverse pathways. It was reported that BP1 is 
overexpressed in 81% breast tumor tissues and, noti-
ceably, in 100% ER- breast tumors. Interestingly, high 
levels of BP1 expression in breast cancer cell lines 
strongly correlate with its tumorigenic potential [15], 
and BP1 expression increases with the progression of 
breast cancer [16]. Recent study found that the stable 
overexpression of BP1 led to inhibition of apoptosis in 
MCF7 breast cancer cells challenged with TNFα [17]. 
The ER negative (ER-) cancers account for about 
one-third of breast cancers, approximately 65,000 a 
year in the United States [18]. While drugs exist that 
can sharply reduce the risk of ER positive (ER+) breast 
cancers, these drugs have no effect on cancers that are 
not hormone sensitive. Drugs such as selective estro-
gen receptor modulators (e.g. tamoxifen) and aroma-
tase inhibitors are used to treat or prevent breast 
cancer in patients with ER+ tumors by directly inhi-
biting or lowering the activity or production of either 
estrogen or estrogen receptors. Unfortunately, no 
drug therapies exist that have an impact on ER- cancer 
[19]. It is likely that the growth and spread of ER- 
cancer cells is driven by factors other than estrogen. 
Because BP1 is expressed in all ER- breast cancers, it 
may have the potential to be a new therapeutic target. 
This study focuses on the functional role of BP1 in the 
proliferation and metastatic potential of ER- Hs578T 
cells, which expresses low BP1 [15].  
MATERIALS AND METHODS 
Cell culture and transfection:  Human breast 
carcinoma cell line Hs578T were cultured in Dulbec-
co's modified Eagle's medium supplemented with 
10% fetal bovine serum and 0.01 mg/ml bovine insu-
lin, in a 37°C humidified incubator with 5% CO2. 
Hs578T cells were stably transfected with BP1 
(pcDNA3.2-BP1), or pcDNA3.2 (Invitrogen, USA) by 
FuGENE 6 transfection reagent (Roche Applied 
Science) according to the manufacturer's instructions. 
Successfully transfected cells were selected in culture 
medium with the addition of 800 µg/ml G418 anti-
biotics (Invitrogen) for two weeks before the indi-
vidual clones were isolated. Three overexpressors 
(O3, O6 and O7) and two controls (V1 and V2) were 
established and maintained in the medium containing 
400 µg/ml of G418.  
RNA isolation and quantitative real-time 
RT-PCR (QPCR): Total RNA was isolated from the 
cell clones, using Trizol reagent (Invitrogen) accord-
ing to the manufacturer’s instruction and purified 
with RNeasy kit (Quiagen). The RNA 6000 Nano Chip 
kit (Agilent) was used for the quality control and 
quantitation of the RNA samples. One microgram of 
total RNA was used for reverse transcription using 
the iScript cDNA Synthesis Kit (Bio-Rad). To verify 
gene expression in transfected cell clones, QPCR was 
performed using the ABI 7300 Real-Time PCR System 
(Applied Biosystems). A final volume of 25µl for each 
reaction consisted of 12.5µl SYBR Green PCR Master Journal of Cancer 2010, 1 
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Mix (Applied Biosystems), 1µl (10µM) of each primer 
(IDT, Coralville, IA, USA), 1µl of cDNA and 9.5µl 
nuclease-free water. The conditions for QPCR were 
50°C for 2 minutes, 95°C for 10 minutes, followed by 
40 cycles of 95°C for 15 seconds and 60°C for 60 
seconds. Dissociation curves were generated for each 
primer set to confirm the specificity of amplifications. 
The Mean Quantity values of target genes mRNA 
expression were normalized by 18S ribosome RNA. 
The primer sequences are for BP1: forward, 
5’-CCTCCCCCAATTTGTCCTACTC-3’ and reverse, 
5’-GGTTGCTGGCAGGACAGGTA-3’; for 18S: for-
ward, 5’-GCCGCTAGAGGTGAAATTCTTG-3’and 
reverse, 5’-CATT CTTGGCAAATGCTTTCG-3’. 
Western blot analysis: Proteins were isolated 
from the cell lines using the T-PER Tissue Protein Ex-
traction Reagent (Fisher Scientific). A 30 µg protein 
from each sample was separated by a 4-20% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis 
(Bio-Rad Laboratories, Hercules, CA, USA) before 
transferring to a nitrocellulose membrane. Rab-
bit-anti-BP1 primary antibody (Novus Biologicals, 
Littleton, CO, USA) was diluted in TNE-Tween20 
buffer (1:1000) followed by incubating with the 
membranes overnight at 4°C. After washing 3 times 
for 15 minutes each, the membrane was incubated in a 
1:1,000 diluted anti-rabbit secondary antibody 
(Pierce/Fisher Scientific) for 2h at room temperature. 
The membranes were submerged in SuperSignal West 
Pico Chemiluminescent Substrate (Fisher Scientific) 
and visualized on a Kodak 2000MM Image Station. 
Protein expression signal intensities were analyzed 
using the Kodak 1D Image Analysis software. After 
detection of BP1 protein, the membranes were treated 
by stripping buffer (62.5 mM Tris-HCl (pH 6.8), 2% 
SDS) at 60°C for 20min. Then 1:20,000 dilution of 
mouse-anti-GAPDH antibody was applied to the 
membrane, and incubated at room temperature for 
1.5h, followed by a 1:1,000 anti-mouse antibody 
(Fisher Scientific) incubation. The membranes were 
visualized and exposed as described before. The rela-
tive intensities of the bands were quantitated, and the 
BP1/GAPDH image quantity ratio was calculated to 
determine the relative expression levels of BP1 protein 
for each cell line. 
Cell proliferation assays: An MTT assay was 
performed to determine the cell proliferation rate 
when BP1 is overexpressed. Three thousand cells per 
well from each clone were seeded in a 96-well plate in 
triplicate, and incubated at 37°C incubator. The MTT 
assays were performed at 24h, 48h and 72h respec-
tively. At each time point, 10µl of the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) reagent (MILLIPORE, Billerica, MA, 
USA) was added to each well. After 4 hours of incu-
bation, cells were lysed by addition of 200μl dime-
thylsulfoxide (DMSO). Absorbance was measured at 
570 nm using a microplate reader (Molecular Devices, 
Sunnyvale, CA, USA). Experiments were repeated 
three times, and the percentage of growth is the av-
erage of the experiments. 
Matrigel invasion assay: A Matrigel invasion 
assay was performed using BD BioCoat™ Matrigel™ 
Invasion Chamber (BD Biosciences, Franklin Lakes, 
NJ, USA). BD BioCoat Matrigel Invasion Chambers 
provide cells with the conditions that allow assess-
ment of their invasive property in vitro. It consists of a 
BD Falcon™ TC Companion Plate with Falcon Cell 
Culture Inserts containing an 8 micron pore size PET 
membrane with a thin layer of matrigel basement 
membrane matrix. The matrigel matrix serves as a 
reconstituted basement membrane in vitro. The layer 
occludes the pores of the membrane, preventing 
non-invasive cells from migrating through the mem-
brane. In contrast, invasive cells are able to detach 
themselves from and invade through the matrigel 
matrix and the 8 micron membrane pores. Briefly, 
Prior to beginning the experiments, a 500μl warm 
(37°C) bicarbonate based serum-free culture medium 
was added to the upper and lower chambers and al-
lowed to rehydrate for 2h in a 37°C cell culture incu-
bator. The 2.5x105 serum-free DMEM treated cells 
from each cell line were seeded onto the top chamber 
of pre-wet inserts. After 24 hours, non-invasive cells 
were removed from the upper surface of the mem-
brane by scrubbing with a cotton swab and the inva-
sive cells present on the bottom of the membrane were 
fixed and stained with Diff-Quick staining solution 
and counted from five microscope fields. Experiments 
were done duplicate for each cell line twice. Cell 
counts were performed on five nonoverlapping ran-
dom fields for each chamber and four chambers were 
counted for each experimental point, and the percen-
tage of invasive cells was normalized to the corres-
ponding controls. 
Microarray assay and data analysis: The Hu-
man Genome Focus Arrays, representing over 8,500 
verified human sequences from the NCBI RefSeq da-
tabase, were used for the study. Total RNA samples 
were purified using RNeasy purification kit 
(QIAGEN, USA) according to the manufacturer’s 
protocol. The detailed protocol for the sample prepa-
ration and microarray processing is available from 
Affymetrix (Santa Clara, CA). Briefly, 5μg of total 
RNA was reverse-transcribed by Superscript II re-
verse transcriptase (Life Technologies, Grand Island, 
NY) using T7-(dT)24 primer containing a T7 RNA 
polymerase promoter. The cDNA then was used to Journal of Cancer 2010, 1 
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synthesize double stranded cDNA for subsequent in 
vitro transcription reaction to generate biotinylated 
complementary RNA (cRNA). Fifteen micrograms of 
fragmented cRNA was hybridized to a Human Ge-
nome Focus Array (Affymetrix) for 16 hours at 45°C 
with constant rotation at 60 rpm. After hybridization, 
the array chip was washed and stained on an Af-
fymetrix FL-450 fluidics station and scanned with the 
GeneChip Scanner 3000 7G. The data was saved by 
AGCC command console software (Affymetrix) as .cel 
file format.  
The array data were analyzed using GeneSpring 
GX 10.0.2 (Agilent Technologies, Santa Clara, CA). 
Samples were grouped into two conditions and sam-
ples within a condition are considered as replicates. 
And for each entity, the average intensity value across 
replicates was used for visualization and analysis. 
Entities are filtered based on their signal intensity 
values by satisfying the upper and lower percentile 
cutoffs 20-100%. Data were processed in GeneSpring 
GX by statistical analysis using unpaired t-test with 
p-value computation done asymptotically (p-value 
cut-off of 0.05). Further analyses were done using fold 
change cut-off of >=2.0. Hierarchical data clustering 
and pathway identification were performed by Ge-
neSpring GX 10.0.2.  
Statistical Analysis: All statistical analyses were 
analyzed by the student t-Test to determine P values 
except for the microarray data. 
RESULTS 
BP1 expression is verified in Hs578T stable cell 
lines: The BP1 mRNA levels in the cloned cell lines, 
including BP1 overexpressors and vector control lines, 
were verified using QPCR, with 18S as an internal 
control. Relative BP1 mRNA levels in O3, O6 and O7 
were significantly increased (p<0.01), more than 15 
fold higher than that of the vector control lines (V1 
and V2) (Figure 1A). But in O1, O2, O4 and O5 cell 
lines, the BP1 mRNA levels were not increased. These 
cell lines could have become resistant to G418 or had 
lower BP1 integration. Therefore, we used O3, O6 and 
O7 for subsequent experiments. To verify BP1 protein 
expression, Western blot analysis was done (Figure 
1B). The upper bands represent BP1 protein, and the 
lower bands are GAPDH used as an internal control. 
The intensities of these bands were quantified by the 
Kodak 1D image analysis software. BP1/GAPDH 
ratios were calculated for each of the three experi-
ments and the average was used for the graph (Figure 
1C). The relative protein expression levels of BP1 in 
O3, O6 and O7 displayed a 2-3.5 fold increase in con-
trast to V1 and V2 (p<0.05), confirming that BP1 pro-
tein was induced in BP1-transfected cells. Part of these 
data were published previously [20]. 
 
 
Figure 1. Verification of BP1 expression in s578T cell clones. A. QRT-PCR analysis of BP1 mRNA levels in BP1 
overexpressing cell lines (O3, O6 and O7) and empty vector control cell lines (V1 and V2). BP1 mRNA levels in the 
overexpressors were significantly increased (p<0.01) compared to the empty vector controls. Each reaction was run twice 
in triplicates. BP1 expression was normalized by 18S. B. Western bolt for BP1 protein expression, using GAPDH as an 
internal control. C. Quantitation of BP1 protein expression, showing a significant increase (p<0.05) in BP1 overexpressors. 
The bolts were photographed and quantitated for each sample in three independent experiments. The analysis was based on 
the average of them. Journal of Cancer 2010, 1 
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BP1 induces more aggressive phenotype in 
Hs578T cells: To test the cell proliferation of BP1 
overexpressors, MTT assays were performed. The cell 
number in each well was directly measured by the UV 
absorbance at each time point. In Figure 2, the absor-
bance data of the vector control lines (V1 and V2) and 
the BP1 overexpressors (O3, O6, O7), collected at 24h, 
48h and 72h were compared. After 24h, the cell num-
bers of BP1-overexpressing cell lines were 2 to 7 times 
higher compared to those of vector control lines 
(p<0.05); this multiple tended to increase at 48h and 
72h, represented by the change of p value, from 
0.046 at 24h to 0.040 at 72h. 
Matrigel resembling the complex extracellular 
environment were used for cell migration assay as a 
model for tumor cell metastasis. In Matrigel assay, the 
number of the migrated cells was counted. Figure 3A 
shows BP1 overexpressing cells (bottom panel, O3, O6 
and O7) with significantly higher number of cells mi-
grated compared to the controls (upper panel, V1 and 
V2). After counting the number of cells in unit areas, 
the average cell numbers per field for each cell line 
were shown (Figure 3B). There were 25 ~ 65 fold in-
crease when BP1 was overexpressed (p<0.001). This 
demonstrates that BP1 overexpression confers a more 
invasive potential in ER- breast cancer cells in vitro.  
 
Figure 2. The effect of BP1 overexpression in 
Hs578T cell proliferation. MTT assays indicate cell 
proliferation rate was significantly higher (P<0.05) in BP1 
overexpressors. The experiments were done three times 
in triplicates for each cell line. 
 
 
 
 
 
Figure 3. Cell invasiveness 
analysis by Matrigel assays. A. 
Matrigel analysis for all five cell 
lines. B. BP1 overexpressing cell 
lines (O3, O6 and O7) exhibited 
very significantly higher invasive-
ness than empty vector control 
cell lines (V1 and V2) (p<0.001). 
Three fields of unit area on each 
membrane were counted for cell 
numbers, and the experiments 
were repeated twice. Data analysis 
was based on the average of pa-
rallel repeats. 
   Journal of Cancer 2010, 1 
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BP1 overexpression affects gene expression pro-
file in Hs578T cell line: Affymetrix Human Genome 
focused array was used to assess gene expression 
profile and identify differentially expressed genes in 
comparison of the BP1 overexpressing cell lines (O3, 
O6 and O7) and empty vector controls (V1 and V2). 
The array data (.CEL file) for all 6 samples (one for 
each clone except V2 was hybridized twice) were 
analyzed using GeneSpring GX. A total of 7843 out of 
8793 passed the filter input satisfying the upper and 
lower percentile cutoffs 20-100% for statistical analy-
sis. Using T Test unpaired asymptotically, 376 entities 
of 7843 satisfy p-value cutoff of 0.05. Further, fold 
change cutoff =>2.0 showed that 71 of 376 genes are 
differentially expressed, with 49 up-regulated and 22 
down-regulated (Table 1). Hierarchical Clustering of 
the 376 transcripts using GeneSpring GX program 
were shown (Figure 4A). From the 71 differentially 
expressed genes, we identified significant pathways 
using the GeneSpring GX satisfying corrected p-value 
cut-off of 0.05, which includes CREB (cAMP respon-
sive element-binding protein) signaling (Figure 4B), 
BCL2L1 (Figure 4C), AKT signaling, apoptosis, an-
drogen receptor pathways, etc.  
 
Figure 4. Gene expression data clustering and pathway identification. A. Hierarchical Entity Trees showing 
376 significantly changed genes using GeneSpring GX. Left 3 panel shows the BP1 overexpressing replicates (O3, 
O6 and O7), while the right panels are the control replicates (V1, V2 and V2’). Color scale bar indicates up-regulation in red 
and down-regulation in green. B. Differentially regulated genes by BP1 involved in CREB1 pathways. CREB1, as 
an oncogenic transcription factor, induces transcription of genes in response to hormonal stimulation of the cAMP pathway. 
C. BP1 regulated genes involved in BCL2L1 pathways. BCL2L1 is a BCL-2 protein family member that act as anti- or 
pro-apoptotic regulators involving in a wide variety of cellular activities. Journal of Cancer 2010, 1 
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Table 1. A representative list of 41 out of 71 differentially expressed genes and their function. 
 
 
DISCUSSION 
A major goal of breast cancer research has been 
to identify specific targets that are unique to particular 
cancer cells and to identify drugs that will kill only 
cancer cells without affecting normal tissue. The 
purpose of this study was to test the effects of BP1 
overexpression in ER- breast cancer, which may shed 
light of the role of BP1 in breast cancer. Eventually, 
the goal is to establish BP1 as a “druggable” target for Journal of Cancer 2010, 1 
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the treatment of ER- breast cancer, and in particular, 
triple-negative breast cancer, which is characterized 
as ER-, progesterone receptor (PR-) negative, and 
HER2-negative. 
ER- breast cancer account for 30-40% of breast 
cancers and are poorly responsive to traditional 
therapies. Current chemotherapy is generally toxic 
and is not specifically targeted to ER- breast cancer. 
This study shows that a high level of BP1 expression 
significantly enhances cell proliferation rate and the 
invasiveness in ER- Hs578T breast cancer cells. These 
data also support the finding that BP1 overexpression 
promotes the survival of MCF7, an ER+ breast cancer 
cell line, when challenged by TNFα treatment [17]. An 
increased proliferation rate and a high degree of in-
vasiveness are two main characteristics of cancer cells; 
these two parameters may determine the severity of 
the cancer [21]. Across the genome, a key alteration of 
cells during cancer development is the up-regulation 
or activation of oncogenic factors, and the 
down-regulation or inactivation of tumor suppressor 
genes [22].  
To elucidate the mechanism of BP1 in cell proli-
feration and invasiveness, a microarray assay has 
identified 376 significantly changed genes using Ge-
neSpring GX as clustered (Figure 4A). A partial gene 
list from the fold change of >=2 is show in Table 1. 
These genes are involved in cell cycle regulation, tu-
mor invasiveness, cell adhesion, receptor signaling, 
cell transformation and tumor progression. Regula-
tion of the expression of these genes by BP1 indicates 
that BP1 is a significant gene which could be a prom-
ising target in breast cancer treatment. Further analy-
sis has identified several important molecular path-
ways using the differentially expressed gene list, in-
cluding CREB signaling (Figure 4B), BCL2L1 (Figure 
4C), AKT signaling, apoptosis, androgen receptor 
pathways, etc. CREB1, as an oncogenic transcription 
factor, induces transcription of genes in response to 
hormonal stimulation of the cAMP pathway. It has 
been reported that CREB may act as a positive tran-
scription regulator of aromatase and hence increased 
expression and estrogen synthesis in breast cancer 
cells [23]. CREB1 expression in breast cancer patients 
is significantly increased in patients with a poor 
prognosis, metastatic disease and nodal involvement 
[24]. CREB1 can be activated through phosphoryla-
tion by a number of kinases, including AKT, protein 
kinase A, and calcium/calmodulin-dependent kinas-
es and regulates genes whose deregulated expression 
promotes oncogenesis, including cyclins, BCL2 family 
members, and EGR1. It was reported that BP1 can 
directly bind to and activate the expression of BCL1, 
which is an antiapoptotic gene and considered to be 
an oncogene [17]. BCL2L1 is a BCL2 protein family 
member that acts as anti- or pro-apoptotic regulators 
involving in a wide variety of cellular activities [25]. 
The proteins encoded by this gene are located at the 
outer mitochondrial membrane, and have been shown 
to regulate outer mitochondrial membrane channel 
(VDAC) opening. VDAC regulates mitochondrial 
membrane potential to control the production  of 
reactive oxygen species and release of cytochrome C 
by mitochondria, both of which are the potent induc-
ers of cell apoptosis. Two alternatively spliced tran-
script variants, which encode distinct isoforms, have 
been reported. The longer isoform acts as an apoptotic 
inhibitor and the  shorter form acts as an apoptotic 
activator. 
CONCLUSIONS 
These data demonstrated that overexpression of 
BP1 significantly enhanced cell proliferation and me-
tastatic potential in ER- Hs578T cells. BP1 may be an 
important modulator for ER- breast tumor metastasis 
through a variety of molecular pathways. Further 
analysis is warranted to establish BP1 as a therapeutic 
target.  
ABBREVIATIONS 
ER: estrogen receptor; RT: reverse transcription; 
QPCR: quantitative real time polymerase chain reac-
tion.  
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